Ashwagandha and ADHD: What the Research Shows About Stress, Focus, Sleep, and Emotional Regulation

Ashwagandha has a growing human literature for stress, sleep, and some cognitive outcomes. The direct ADHD evidence is much thinner.

As of the August 15, 2026 literature check for this guide, the most directly relevant pediatric ADHD study we found is a small randomized study of 58 children ages 5–12 that is available as a preprint, not a peer-reviewed PubMed-indexed clinical paper. A separate 2026 randomized trial enrolled 85 healthy children with parent-reported attention, concentration, or memory concerns, but those children were not an ADHD treatment cohort.

That distinction matters. A positive stress trial, a healthy-child cognition trial, and a small ADHD preprint are three different levels of evidence.

Bottom line: ashwagandha should not currently be presented as an established ADHD treatment or stimulant alternative. The stronger evidence is indirect—stress and sleep—and the 2026 safety literature makes product identity, liver risk, thyroid status, pregnancy, and medication context especially important.

Evidence at a glance

The direct ADHD evidence is not yet mature

The pediatric ADHD study frequently cited online randomized 58 children with mild ADHD to an ashwagandha root aqueous extract or placebo for 56 days and reported favorable ADHD Rating Scale and executive-function outcomes.

That is scientifically interesting. It is also important to label the evidence correctly:

• the study is small;
• the treatment period was short;
• the population was children with mild ADHD;
• the formulation was a defined aqueous root extract;
• the report is currently available as a preprint;
• there is not yet a replicated body of peer-reviewed ADHD trials establishing efficacy, dose, long-term safety, or medication-combination safety.

A preprint can justify further research. It should not be treated as settled pediatric treatment evidence.

The 2026 healthy-child cognition trial is not an ADHD trial

A 2026 randomized, double-blind, placebo-controlled study enrolled 85 healthy children ages 6–12 whose parents reported concerns about attention, concentration, or memory.

The ashwagandha group improved on speed of information processing. That finding is relevant to cognition research, but the study did not establish that ashwagandha treats diagnosed ADHD, reduces core ADHD symptoms, or can replace medication.

This is a common evidence-conversion error on supplement sites: “attention improved in a non-ADHD sample” becomes “supplement treats ADHD.” This guide does not make that jump.

Stress evidence may still matter—indirectly

Stress can worsen sleep, irritability, perceived cognitive load, and day-to-day functioning in people with ADHD. Ashwagandha has substantially more research for stress than for ADHD.

That can make stress a relevant co-occurring target. It does not mean ADHD is caused by high cortisol or that lowering cortisol treats the disorder.

A stress outcome should stay a stress outcome.

Sleep evidence may matter—indirectly

Sleep problems are common in ADHD, and poor sleep can worsen attention and emotional regulation the next day. Ashwagandha has a small randomized-trial literature for sleep in adults.

If a sleep outcome improves, that may improve daytime function. It should not be converted into evidence of a direct effect on ADHD neurobiology or executive function.

For ADHD-specific sleep evidence, see the dedicated melatonin for ADHD sleep guide.

The 2026 safety picture looks contradictory—but it is not

Two recent evidence streams can appear to conflict:

1. A 2026 systematic review of 23 trials / 2,317 participants found standardized root-only extracts were generally well tolerated in healthy adults across the studied doses and durations, with no serious adverse events attributed to the extracts.
2. A separate 2026 scoping review identified 25 patients with published ashwagandha-associated liver injury, usually appearing after weeks of use and often showing a cholestatic or mixed injury pattern.

Both findings can be true.

Randomized trials are useful for common short-term adverse effects in defined products and selected populations. They are usually too small to reliably detect rare idiosyncratic liver injury. Case reports and case series are much better at flagging unusual harms, but they cannot calculate a precise population incidence.

That is why “trials looked safe” does not mean “rare liver injury is disproven.”

What the liver-injury literature actually shows

The 2026 scoping review synthesized 13 publications covering 25 patients.

Reported features included:

• onset usually after weeks of use;
• jaundice and itching in many cases;
• cholestatic or mixed biochemical patterns more often than purely hepatocellular injury;
• recovery in most patients after stopping the product and supportive care;
• severe outcomes in a minority, including liver transplantation in one case and deaths among patients with pre-existing cirrhosis who decompensated.

This does not mean liver injury is common. It means there is now enough repeated clinical reporting that the risk should not be omitted from an evidence-based safety section.

Root-only standardized extracts are not interchangeable with every product

The reassuring 2026 safety review deliberately focused on single-ingredient standardized root-only extracts in generally healthy adults.

That evidence cannot automatically be generalized to:

• root-and-leaf extracts;
• multi-ingredient “adaptogen” blends;
• gummies with additional actives;
• raw powders of uncertain identity;
• products with different withanolide profiles;
• products with poor quality control;
• children;
• pregnancy or breastfeeding;
• people with liver, thyroid, autoimmune, or other chronic disease;
• long-term use beyond the durations studied.

“Contains ashwagandha” is not a sufficient description of a research intervention.

Medication and condition context

NCCIH advises caution or avoidance in several situations and notes potential interactions with medications.

If someone takes prescription ADHD medication, the prescriber or pharmacist managing that treatment is the appropriate person to review supplement co-use.

Why this page does not give a pediatric ADHD dose

A trial needs a defined dose and formulation. That does not convert the study exposure into a consumer protocol.

The direct ADHD evidence is too preliminary to establish:

• a universal pediatric dose;
• a mg/kg rule;
• a withanolide target;
• a morning-versus-evening ADHD schedule;
• an “as-needed” focus dose;
• a stimulant-combination protocol;
• a long-term maintenance regimen.

This page reports study designs as evidence context rather than turning them into instructions.

Evidence-applicability ledger

Unanswered questions worth tracking

1. Will the pediatric ADHD findings survive peer review and independent replication?
2. Are benefits specific to mild ADHD, a stress-heavy subgroup, or the tested product?
3. Do teacher-rated and objective attention outcomes replicate parent/clinician ratings?
4. Does ashwagandha add benefit to stimulant or non-stimulant treatment?
5. What is the long-term pediatric safety profile?
6. Which preparation characteristics matter: root-only versus root-and-leaf, withanolide profile, or extraction method?
7. Can any biomarkers predict benefit or liver risk?
8. What is the true incidence of ashwagandha-associated liver injury in real-world users?

Frequently asked questions

Does ashwagandha treat ADHD?

Not on current evidence. Direct ADHD data are very limited, and the most directly relevant pediatric randomized report is currently a small preprint.

Is there any direct ADHD study?

Yes. A 58-child randomized study reported favorable results over 56 days, but it has not yet become a replicated peer-reviewed ADHD evidence base.

Does ashwagandha improve focus?

A 2026 randomized trial in healthy children with parent-reported attention or memory concerns found an improvement in speed of information processing. That is not the same as proving treatment of diagnosed ADHD.

Is ashwagandha safe for the liver?

Most people in short controlled trials of standardized root extracts did not develop clinically important liver abnormalities, but rare idiosyncratic liver injury is now supported by repeated published case reports and case series. Those two facts are not contradictory.

Can ashwagandha be combined with stimulant medication?

Direct interaction and coadministration evidence is limited. Review co-use with the prescriber or pharmacist managing the ADHD medication rather than assuming a supplement is interaction-free.

What dose should a child with ADHD take?

There is no evidence-based universal pediatric ADHD dose for ashwagandha. A dose used in a small trial should not be converted into an unsupervised protocol.

Sources

1. Jain M, et al. Ashwagandha Root Extract in Treatment of Mild Attention Deficit Hyperactivity Disorder (ADHD) in Children Aged 5–12 Years: A Prospective, Double-Blind, Randomized, Placebo Controlled Study. Preprint. https://figshare.com/articles/preprint/_b_Ashwagandha_Root_Extract_in_Treatment_of_Mild_Attention_Deficit_Hyperactivity_Disorder_ADHD_in_Children_Aged_5_12_Years_A_Prospective_b_b_Double-Blind_Randomized_Placebo_Controlled_Study_b_/27302499
2. A clinical assessment of the therapeutic effects of Ashwagandha root extract on cognitive performance, sleep, and fatigue in children aged 6–12 years. 2026. PMID 41889719. https://pubmed.ncbi.nlm.nih.gov/41889719/
3. McIntyre D, et al. Ashwagandha (Withania somnifera)-Associated Liver Injury: A Scoping Review of Clinical Characteristics and Safety Considerations. 2026. PMID 42367407. https://pubmed.ncbi.nlm.nih.gov/42367407/
4. Coope OC, et al. Back to the Roots: Safety and Tolerability of Standardised Ashwagandha Root Extract in Healthy Adults—A Systematic Review of Biomarkers and Adverse Events. 2026. PMID 42198398. https://pubmed.ncbi.nlm.nih.gov/42198398/
5. National Center for Complementary and Integrative Health. Ashwagandha: Usefulness and Safety. https://www.nccih.nih.gov/health/ashwagandha
6. Thanawala S, et al. Efficacy and safety of Ashwagandha root extract sustained-release capsules in healthy adult stressed subjects. 2026. PMID 41824889. https://pubmed.ncbi.nlm.nih.gov/41824889/
7. Safety and tolerability of Ashwagandha root extract in healthy adults: a prospective, non-comparative study. 2026. PMID 42253745. https://pubmed.ncbi.nlm.nih.gov/42253745/